» Articles » PMID: 37920127

Regional Differences and Coronary Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction

Abstract

Aims: In heart failure with preserved ejection fraction (HFpEF), regional heterogeneity of clinical phenotypes is increasingly recognized, with coronary microvascular dysfunction (CMD) potentially being a common shared feature. We sought to determine the regional differences in clinical characteristics and prevalence of CMD in HFpEF.

Methods And Results: We analysed clinical characteristics and CMD in 202 patients with stable HFpEF (left ventricular ejection fraction ≥40%) in Finland, Singapore, Sweden, and United States in the multicentre PROMIS-HFpEF study. Patients with unrevascularized macrovascular coronary artery disease were excluded. CMD was assessed using Doppler echocardiography and defined as coronary flow reserve (adenosine-induced vs. resting flow) < 2.5. Patients from Singapore had the lowest body mass index yet highest prevalence of hypertension, dyslipidaemia, and diabetes; patients from Finland and Sweden were oldest, with the most atrial fibrillation, chronic kidney disease, and high smoking rates; and those from United States were youngest and most obese. The prevalence of CMD was 88% in Finland, 80% in Singapore, 77% in Sweden, and 59% in the United States; however, non-significant after adjustment for age, sex, N-terminal pro-brain natriuretic peptide, smoking, left atrial reservoir strain, and atrial fibrillation. Associations between CMD and clinical characteristics did not differ based on region (interaction analysis).

Conclusions: Despite regional differences in clinical characteristics, CMD was present in the majority of patients with HFpEF across different regions of the world with the lowest prevalence in the United States. This difference was explained by differences in patient characteristics. CMD could be a common therapeutic target across regions.

Citing Articles

Evolution of Coronary Microvascular Dysfunction Prevalence over Time and Across Diagnostic Modalities in Patients with ANOCA: A Systematic Review.

Zimmerli A, Salihu A, Antiochos P, Lu H, Pitta Gros B, Berger A J Clin Med. 2025; 14(3).

PMID: 39941504 PMC: 11818762. DOI: 10.3390/jcm14030829.


2024 update in heart failure.

Beghini A, Sammartino A, Papp Z, von Haehling S, Biegus J, Ponikowski P ESC Heart Fail. 2024; 12(1):8-42.

PMID: 38806171 PMC: 11769673. DOI: 10.1002/ehf2.14857.


Expanding landscape of coronary microvascular disease in co-morbid conditions: Metabolic disease and beyond.

McCallinhart P, Chade A, Bender S, Trask A J Mol Cell Cardiol. 2024; 192:26-35.

PMID: 38734061 PMC: 11340124. DOI: 10.1016/j.yjmcc.2024.05.004.


Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction.

Erhardsson M, Faxen U, Venkateshvaran A, Svedlund S, Saraste A, Fermer M ESC Heart Fail. 2023; 10(6):3729-3734.

PMID: 37920127 PMC: 10682847. DOI: 10.1002/ehf2.14569.

References
1.
Shah S, Katz D, Selvaraj S, Burke M, Yancy C, Gheorghiade M . Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2014; 131(3):269-79. PMC: 4302027. DOI: 10.1161/CIRCULATIONAHA.114.010637. View

2.
Shah S, Lam C, Svedlund S, Saraste A, Hage C, Tan R . Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J. 2018; 39(37):3439-3450. PMC: 6927847. DOI: 10.1093/eurheartj/ehy531. View

3.
Hage C, Svedlund S, Saraste A, Faxen U, Benson L, Fermer M . Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study. J Card Fail. 2020; 26(11):1016-1021. DOI: 10.1016/j.cardfail.2020.08.010. View

4.
Solomon S, McMurray J, Claggett B, de Boer R, DeMets D, Hernandez A . Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022; 387(12):1089-1098. DOI: 10.1056/NEJMoa2206286. View

5.
Hirata Y, Sugiyama S, Yamamoto E, Matsuzawa Y, Akiyama E, Kusaka H . Endothelial function and cardiovascular events in chronic kidney disease. Int J Cardiol. 2014; 173(3):481-6. DOI: 10.1016/j.ijcard.2014.03.085. View